Odomzo Approved for Recurring Basal Cell Carcinoma
Title: Odomzo Approved for Recurring Basal Cell CarcinomaCategory: Health NewsCreated: 7/24/2015 12:00:00 AMLast Editorial Review: 7/27/2015 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 27, 2015 Category: Cancer & Oncology Source Type: news
FDA Approves New Drug for Locally Advanced Skin Cancer (FREE)
By Kristin J. Kelley
Edited by Susan Sadoughi, MD
Sonidegib (brand name: Odomzo) has been approved for the treatment of locally advanced basal cell carcinoma. It is indicated for adults … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2015 Category: Primary Care Source Type: news
New Skin Cancer Drug Approved by FDA
Odomzo is a pill for locally advanced basal cell carcinoma (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - July 26, 2015 Category: Cancer & Oncology Source Type: news
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable(1)
Basal cell carcinoma, the most common form of skin cancer, can be highly disfiguring at advanced stages(2)
Od... Biopharmaceuticals, Oncology, FDANovartis, Odomzo, sonidegib, basal cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 24, 2015 Category: Pharmaceuticals Source Type: news
New Skin Cancer Drug Approved by FDA
Odomzo is a pill for locally advanced basal cell carcinoma (Source: WebMD Health)
Source: WebMD Health - July 24, 2015 Category: Consumer Health News Source Type: news
FDA approves hedgehog pathway inhibitor for locally advanced BCC
Sonidegib, a hedgehog pathway inhibitor, has been approved for treating patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy, the Food and Drug Administration <a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 24, 2015 Category: Dermatology Source Type: news
New Skin Cancer Drug Approved by FDA
Odomzo is a pill for locally advanced basal cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 24, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Dermatology, Nursing, Oncology, Pharmacy, News, Source Type: news
FDA approves once-a-day pill for common skin cancer
Stephen FellerSILVER SPRING, Md., July 24 (UPI) -- The FDA announced that it approved the once-a-day pill Odomzo for patients with recurrent basal cell carcinoma or who can't have surgery or radiation therapy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 24, 2015 Category: Consumer Health News Source Type: news
Odomzo Approved for Recurring Basal Cell Carcinoma
A common form of skin cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 24, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news
FDA Approves Drug for Basal Cell Carcinoma
(MedPage Today) -- Sonidegib becomes second hedgehog inhibitor for locally advanced disease. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 24, 2015 Category: American Health Source Type: news
FDA Approves Sonidegib (Odomzo) for Basal Cell CarcinomaFDA Approves Sonidegib (Odomzo) for Basal Cell Carcinoma
The drug is indicated for use in locally advanced disease News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 24, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
New Skin Cancer Drug Approved by FDA
Odomzo is a pill for locally advanced basal cell carcinoma
Source: HealthDay
Related MedlinePlus Pages: Medicines, Skin Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 24, 2015 Category: Consumer Health News Source Type: news
FDA approves new treatment for most common form of advanced skin cancer
The U.S. Food and Drug Administration today approved Odomzo (sonidegib) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 24, 2015 Category: American Health Source Type: news
Odomzo Approved for Recurring Basal Cell Carcinoma
A common form of skin cancer (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - July 24, 2015 Category: Cancer & Oncology Source Type: news
